Quick Answer
Enveric Biosciences, Inc. reported Cash and Equivalents of $431.4 thousand for fiscal year 2019.
Enveric Biosciences, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2019 | $431.4K | -68.5% |
| 2018 | $1.37M | -71.9% |
| 2017 | $4.88M | +253.8% |
| 2016 | $1.38M | -26.5% |
| 2015 | $1.88M | +36832.8% |
| 2014 | $5.1K | +1942.2% |
| 2013 | $249.00 | -82.0% |
| 2012 | $1.4K | -92.4% |
| 2011 | $18.2K | +1519.1% |
| 2010 | $1.1K | -37.2% |
| 2009 | $1.8K | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2020 | $2.84M | +468.4% | +36.0% |
| June 30, 2020 | $2.09M | +30.4% | +64.7% |
| March 31, 2020 | $1.27M | -26.4% | +193.8% |
| December 31, 2019 | $431.4K | -68.5% | -13.7% |
| September 30, 2019 | $499.7K | -75.8% | -68.8% |
| June 30, 2019 | $1.60M | +75.0% | -7.1% |
| March 31, 2019 | $1.72M | -2.3% | +25.7% |
| December 31, 2018 | $1.37M | -71.9% | -33.5% |
- Enveric Biosciences, Inc. showed a decrease of -68.5% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2009–2019 period, Enveric Biosciences, Inc.’s cash and equivalents has grown by 23973.7% (from $1.8 thousand to $431.4 thousand).
- The most recent figure is from Enveric Biosciences, Inc.’s fiscal year 2019 report (Form 10-K), filed with the SEC on March 25, 2020.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: